Letizia Foroni

Analysis of paired presentation and relapse samples in T-ALL suggests that, at least in some patients, Notch-1 mutations may be acquired as a secondary event

David C. Linch, Rosemary E. Gale, Marc R. Mansour, 2007 .

A RAPID METHOD FOR THE DETECTION OF CLONAL-B CELL EXPANSION AND MINIMAL RESIDUAL DISEASE (MRD) IN ALL BY THE POLYMERASE CHAIN-REACTION (PCR)

Letizia Foroni, Jc Yaxley, Jcs Chim, 1993 .

The role of HTLV-1 clonality, proviral structure, and genomic integration site in adult T-cell leukemia/lymphoma.

Anat Melamed, Charles R. M. Bangham, Graham P. Taylor, 2014, Blood.

Regulation of myeloid leukemia by the cell fate determinant Musashi

Takahiro Ito, Bryan Zimdahl, Tannishtha Reya, 2010, Nature.

Core binding factor genes and human leukemia.

Letizia Foroni, L. Foroni, S. Hart, 2002, Haematologica.

The molecular characterization of Beta globin gene in thalassemia patients reveals rare and a novel mutations in Pakistani population.

Humaira Yasmeen, Letizia Foroni, Shahida Hasnain, 2016, European journal of medical genetics.

Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies.

Kostas Stamatopoulos, Xavier Brochet, Nikolaos Laoutaris, 2012, Blood.

Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

Katayoun Rezvani, Letizia Foroni, K. Rezvani, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Technical aspects and clinical applications of measuring BCR‐ABL1 transcripts number in chronic myeloid leukemia

Letizia Foroni, John Goldman, D. Marin, 2009, American journal of hematology.

RT-qPCR and RT-Digital PCR: A Comparison of Different Platforms for the Evaluation of Residual Disease in Chronic Myeloid Leukemia.

Jim F Huggett, Alexandra S Whale, Simon Cowen, 2016, Clinical chemistry.